Azacitidine Ropeginterferon trial NCT07646821
Phase 1b/2 trial NCT07646821 adds ropeginterferon alfa-2b to azacitidine in TP53-mutated MDS/AML; ChEMBL, ClinicalTrials.gov and DepMap data as of 2026-11-15.
BioQ Blog
Every BioQ post about azacitidine: real search results, sources and the query to repeat it.
Phase 1b/2 trial NCT07646821 adds ropeginterferon alfa-2b to azacitidine in TP53-mutated MDS/AML; ChEMBL, ClinicalTrials.gov and DepMap data as of 2026-11-15.
NCT07885397 tests sonrotoclax in high-risk MDS; ChEMBL potency and 35 ClinicalTrials.gov studies show what is already known about the drug and its target.